Diabetes Type 1NCT06529705
Performance and Safety Evaluation of the EkiYou V2 Application in Patients With Diabetes Using Multiple Daily Insulin Injections (EkiYou-Study1)
A study testing EkiYou V2 in people with Diabetes Type 1 and Diabetes Type 2 on Insulin, run by University Hospital, Montpellier at 1 site in France.
Trial summary
EkiYou-Study-1 is an interventional before/after clinical investigation according to EU 2017/745. It is conducted in 21 adults with diabetes and treated by multiple daily insulin injections. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Diabetes Type 1, Diabetes Type 2 on Insulin, Pancreatogenous Diabetes
- What is being tested?
- EkiYou V2
- Type of treatment
- Medical device
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 21 participants
- Where
- 1 siteFrance
- Study dates
- 19 Aug 2024to 27 Mar 2025
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Be over 18 years old;
- Have type 1, type 2, or pancreatogenic diabetes;
- Have been treated with multiple daily injections of insulin in a basal/bolus regimen for at least 6 months;
- Be using a continuous glucose monitoring device such as Dexcom G6, Dexcom One or Freestyle Libre for at least 2 weeks;
- Have a time in the glycemic target range (70-180 mg/dl) of less than 70%;
- Require at least 15 units of insulin therapy per day;
Show all 12Show fewer
- Use a rapid-acting insulin compatible with the device, such as Novorapid, Humalog, Apidra, Asparte, Sanofi, Fiasp, or Lyumjev;
- Use a long-acting insulin compatible with the device, such as Lantus, Abasaglar, Toujeo, Levemir, or Tresiba;
- Be able to read and use a smartphone;
- Have no visual impairment requiring a specific font for smartphones;
- Have basic knowledge of smartphone use;
- Indicate their willingness to follow the protocol and sign a written informed consent
Who cannot join
- Ketoacidosis or severe level 3 hypoglycemia requiring third-party intervention within 6 months prior to inclusion;
- Treatment with any hypoglycemia-inducing agent other than insulin (including sulfonylureas and SGLT-2 inhibitors);
- Daily insulin requirement exceeding 200 U/day;
- Suffering from gastroparesis;
- Pancreatopathy secondary to chronic alcoholism;
- Known medical condition that, in the investigator's opinion, may interfere with the protocol;
Show all 11Show fewer
- Participation in another clinical trial or administration of an unapproved medication within 4 weeks prior to screening;
- Not affiliated with a social security system;
- Vulnerable subject: minors, or adults under protection as defined by the Public Health Code, pregnant or breastfeeding women, subjects under guardianship or deprived of liberty;
- Person under legal protection;
- Person participating in another study with an ongoing exclusion period
Trial locations and contacts
1 site in 1 country.
France1 site
Centre Hospitalier Universitaire de Montpellier
Montpellier, France, 34000
About this study
EkiYou-Study-1 is an interventional before/after clinical investigation according to EU 2017/745. It is conducted in 21 adults with diabetes and treated by multiple daily insulin injections.
After a run-in period of 2 weeks, participants will receive for 6 weeks EkiYou V2 application that will help them to estimate their daily bolus and basal insulin doses. This device weekly adjusts insulin parameters including : basal insulin dose, insulin to carb ratios and correction factor.
The aim of the study is to assess the safety and performance of EkiYou V2 device. Data on glycemic control, safety, quality of life and satisfaction of participants will be collected.
Read the detailed description
Participants of the study must be adults treated by multiple daily insulin injection in a basal/bolus insulin schema and users of a continuous glucose monitor (CGM). The study involves 5 visits, each two weeks. Participants will be included for 8 weeks divided in two distinct periods :
- Run-in period for two weeks to collect glycemic control at baseline with their standard insulin management
- Intervention period for 6 weeks where participant will receive the investigational device EkiYou V2 to manage their insulin injection.
EkiYou V2 device is a new version of the previously CE-Marked device EkiYou V1. It is a decision support that include the following features to participants:
- Carbohydrate counting through an extensive food database with more than 200k items.
- Bolus calculation based on their meal, physical activity and blood glucose.
- Bolus correction advice.
- Long-acting insulin reminders and automatic periodic titration.
- Insulin-to-carb ratios and correction factor automatic adjustment.
- Being tested
- EkiYou V2
- Keywords
- Decision support system, Digital health, Continuous glucose monitoring, Precision insulin management, Insulin titration
- Medical subject headings
- Diabetes Mellitus, Type 1
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
EkiYou V2Device
Use of a mobile application that help users to evaluate their daily bolus and basal insulin needs, and that adjusts at weekly basis their insulin to carb ratios, correction factor and basal dose.
| Study group | Role | What they receive |
|---|---|---|
| Adults with diabetes treated by MDI | Experimental | Not described Receives: Device: EkiYou V2 |
What is being measured
The primary outcome is the main question the study is designed to answer.
Change in the percentage of time in range 70-180 mg/dL
Time in range is the amount of time spent in the target glucose range-between 70 and 180 mg/dL-as measured by CGM
Measured: Through study completion, an average of 8 weeks
Secondary outcomes (39)
Number of non-serious adverse events related or unrelated to the device
Severe hypoglycemia (Level 3) with blood glucose below 54 mg/dL and requiring assistance from an external person for carbohydrates intake or glucagon use.
Measured: Through study completion, an average of 8 weeks
Number of non-serious adverse events related or unrelated to the device
Severe hyperglycemia (Level 3) defined by the presence of ketonemia > 3 mmol/L or ketonemia > 1 mmol/L and requiring consultation with a healthcare professional.
Measured: Through study completion, an average of 8 weeks
Number of serious clinical adverse events (SAEs)
Number of severe level 3 hypoglycemic events requiring hospitalization
Measured: Through study completion, an average of 8 weeks
Number of serious clinical adverse events (SAEs)
Number of episodes of diabetic ketoacidosis requiring hospitalization
Measured: Through study completion, an average of 8 weeks
Number of other serious adverse events related or unrelated to the device
Measured: Through study completion, an average of 8 weeks
Number of non-serious and unexpected adverse events related to the device
Measured: Through study completion, an average of 8 weeks
Change in the percentage of time below 54 mg/dL
Percentage of time with glucose below 54 mg/dL as measured by CGM
Measured: 2 weeks follow-up
Change in the percentage of time below 54 mg/dL
Percentage of time with glucose below 54 mg/dL as measured by CGM
Measured: 8 weeks follow-up
Change in the percentage of time below 70 mg/dL
Percentage of time with glucose below 70 mg/dL as measured by CGM
Measured: 2 weeks follow-up
Change in the percentage of time below 70 mg/dL
Percentage of time with glucose below 70 mg/dL as measured by CGM
Measured: 8 weeks follow-up
Change in the percentage of time above 180 mg/dL
Percentage of time with glucose above 180 mg/dL as measured by CGM
Measured: 2 weeks follow-up
Change in the percentage of time above 180 mg/dL
Percentage of time with glucose above 180 mg/dL as measured by CGM
Measured: 8 weeks follow-up
Change in the percentage of time above 250 mg/dL
Percentage of time with glucose above 250 mg/dL as measured by CGM
Measured: 2 weeks follow-up
Change in the percentage of time above 250 mg/dL
Percentage of time with glucose above 250 mg/dL as measured by CGM
Measured: 8 weeks follow-up
Change in the Glucose Management Indicator (GMI)
GMI as measured by CGM
Measured: 2 weeks follow-up
Change in the Glucose Management Indicator (GMI)
GMI as measured by CGM
Measured: 8 weeks follow-up
Percentage of patients with time in range 70-180 mg/dL above or equal to 70%
Time in range 70-180 mg/dL as measured by CGM
Measured: 2 weeks follow-up
Percentage of patients with time in range 70-180 mg/dL above or equal to 70%
Time in range 70-180 mg/dL as measured by CGM
Measured: 8 weeks follow-up
Change in Mean blood glucose level
Mean sensor glucose as measured by CGM
Measured: 2 weeks follow-up
Change in Mean blood glucose level
Mean sensor glucose as measured by CGM
Measured: 8 weeks follow-up
Change in Coefficient of variation of blood glucose
Coefficient of variation of blood glucose as measured by CGM
Measured: 2 weeks follow-up
Change in Coefficient of variation of blood glucose
Coefficient of variation of blood glucose as measured by CGM
Measured: 8 weeks follow-up
Number of level 2 hypoglycemic episodes
Defined as blood glucose below 54 mg/dL for more than 15 minutes
Measured: 2 weeks follow-up
Number of level 2 hypoglycemic episodes
Defined as blood glucose below 54 mg/dL for more than 15 minutes
Measured: 8 weeks follow-up
Total Daily Insulin (Units/kg)
Measured: 2 weeks follow-up
Change in Total Daily Insulin (Units/kg)
Measured: 8 weeks follow-up
Total Insulin Delivered Via Basal (Units/kg)
Measured: 2 weeks follow-up
Change in total Insulin Delivered Via Basal (Units/kg)
Measured: 8 weeks follow-up
Number per day and total Insulin Delivered Via Bolus (Units/kg)
Measured: 2 weeks follow-up
Change in number per day and total Insulin Delivered Via Bolus (Units/kg)
Measured: 8 weeks follow-up
Number of connectivity issues with the application reported by the user
Measured: 8 weeks follow-up
Questionnaire System Usability scale
Device usability questionnaire. The lower the score, more the participant agrees with the item; a higher score indicates disagreement with the item.
Measured: 8 weeks follow-up
Diabetes Treatment Satisfaction Questionnaire (DTSQ)
Quality of life associated with diabetes questionnaire. Treatment Satisfaction: Items 1, 4, 5, 6, 7 \& 8 are summed to produce a Treatment Satisfaction score (range: 0 to 36). The higher the score, the greater the satisfaction with treatment.
Individual satisfaction with treatment items (items 1, 4, 5, 6, 7 \& 8) can be considered separately: All rated: 6 (very satisfied, convenient, flexible, etc.) to 0 (very dissatisfied, inconvenient, inflexible, etc.). The higher the score, the greater the satisfaction with each aspect of treatment.
'Perceived frequency of hyperglycaemia' (item 2) \& 'Perceived frequency of hypoglycaemia' (item 3): Both rated: 6 ('most of the time') to 0 ('none of the time'). Here, lower scores indicate blood glucose levels closer to the ideal. Higher scores indicate problems
Measured: At inclusion visit
Diabetes Treatment Satisfaction Questionnaire (DTSQ)
Quality of life associated with diabetes questionnaire Treatment Satisfaction: Items 1, 4, 5, 6, 7 \& 8 are summed to produce a Treatment Satisfaction score (range: 0 to 36). The higher the score, the greater the satisfaction with treatment.
Individual satisfaction with treatment items (items 1, 4, 5, 6, 7 \& 8) can be considered separately: All rated: 6 (very satisfied, convenient, flexible, etc.) to 0 (very dissatisfied, inconvenient, inflexible, etc.). The higher the score, the greater the satisfaction with each aspect of treatment.
'Perceived frequency of hyperglycaemia' (item 2) \& 'Perceived frequency of hypoglycaemia' (item 3): Both rated: 6 ('most of the time') to 0 ('none of the time'). Here, lower scores indicate blood glucose levels closer to the ideal. Higher scores indicate problems
Measured: 8 weeks follow-up
Hypoglycemia Fear Survey 2 (HFS II)
Fear of hypoglycemia questionnaire. Behavioral Subscale, Items: 1-15 Score Range: 0 to 75. Higher scores indicate more frequent behaviors aimed at avoiding hypoglycemia, reflecting a greater fear of low blood sugar episodes.
Worry Subscale, Items: 16-33 Score Range: 0 to 90. Higher scores suggest greater concern or anxiety about the consequences of hypoglycemia, including physical symptoms and impact on daily activities.
Total Score Range: 0 to 165 (sum of both subscales). A higher total score indicates a more intense overall fear of hypoglycemia, affecting both behavior and emotional well-being.
Measured: At inclusion visit
Hypoglycemia Fear Survey 2 (HFS II)
Fear of hypoglycemia questionnaire. Behavioral Subscale, Items: 1-15 Score Range: 0 to 75. Higher scores indicate more frequent behaviors aimed at avoiding hypoglycemia, reflecting a greater fear of low blood sugar episodes.
Worry Subscale, Items: 16-33 Score Range: 0 to 90. Higher scores suggest greater concern or anxiety about the consequences of hypoglycemia, including physical symptoms and impact on daily activities.
Total Score Range: 0 to 165 (sum of both subscales). A higher total score indicates a more intense overall fear of hypoglycemia, affecting both behavior and emotional well-being.
Measured: 8 weeks follow-up
Number of daily insulin injections calculated from application data
Measured: 8 weeks follow-up
Average number of daily interactions calculated from application data
Measured: 8 weeks follow-up
Number of active application users
Defined as at least 14 recorded injections in the application over a 2-week period
Measured: 8 weeks follow-up
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted31 Jul 2024
- Study start19 Aug 2024
- Primary completion27 Mar 2025
- Study completion27 Mar 2025
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Diabetes Type 1Studies of the same condition, open and under way.
- More trials run by University Hospital, MontpellierThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Other
- Allocation
- Not applicable
- Intervention model
- Single group
- Model description
- Adults with type 1, type 2 diabetes or pancreatogenic diabetes treated by multiple daily insulin injections
- Masking
- None (open label)
- Enrolment
- 21 participants (actual)
Sponsor and investigators
- Lead sponsor
- University Hospital, Montpellier
- Sponsor type
- University, hospital or other
- Collaborators
- DiappyMed
- Responsible party
- Sponsor
- Investigators
- Orianne VILLARD, MD, Principal investigator, CHU de Montpellier
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06529705
- Sponsor's protocol ID
- RECHMPL23_0453
- Other IDs
- 2024-A00433-44
- Status last verified
- Sep 2025
- First submitted
- 15 Jul 2024
- Last updated
- 15 Sep 2025
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 15 Sep 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Performance and Safety Evaluation of the EkiYou V2 Application in Patients With Diabetes Using Multiple Daily Insulin Injections (EkiYou-Study1)
- ClinicalTrials.gov ID
- NCT06529705
- Acronym / sponsor ID
- RECHMPL23_0453
- Keywords
- Decision support system, Digital health, Continuous glucose monitoring, Precision insulin management, Insulin titration
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 21 participants (actual)
- Lead sponsor
- University Hospital, MontpellierUniversity, hospital or other
- Collaborators
- DiappyMed
- Study start
- 19 Aug 2024 (actual)
- Primary completion
- 27 Mar 2025 (actual)
- Study completion
- 27 Mar 2025 (actual)
- First posted
- 31 Jul 2024 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
EkiYou-Study-1 is an interventional before/after clinical investigation according to EU 2017/745. It is conducted in 21 adults with diabetes and treated by multiple daily insulin injections.
After a run-in period of 2 weeks, participants will receive for 6 weeks EkiYou V2 application that will help them to estimate their daily bolus and basal insulin doses. This device weekly adjusts insulin parameters including : basal insulin dose, insulin to carb ratios and correction factor.
The aim of the study is to assess the safety and performance of EkiYou V2 device. Data on glycemic control, safety, quality of life and satisfaction of participants will be collected.
Detailed description
Participants of the study must be adults treated by multiple daily insulin injection in a basal/bolus insulin schema and users of a continuous glucose monitor (CGM). The study involves 5 visits, each two weeks. Participants will be included for 8 weeks divided in two distinct periods :
- Run-in period for two weeks to collect glycemic control at baseline with their standard insulin management
- Intervention period for 6 weeks where participant will receive the investigational device EkiYou V2 to manage their insulin injection.
EkiYou V2 device is a new version of the previously CE-Marked device EkiYou V1. It is a decision support that include the following features to participants:
- Carbohydrate counting through an extensive food database with more than 200k items.
- Bolus calculation based on their meal, physical activity and blood glucose.
- Bolus correction advice.
- Long-acting insulin reminders and automatic periodic titration.
- Insulin-to-carb ratios and correction factor automatic adjustment.
Study design
- Primary purpose
- Other
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
- Model description
- Adults with type 1, type 2 diabetes or pancreatogenic diabetes treated by multiple daily insulin injections
| Arm | Type | Receives |
|---|---|---|
| Adults with diabetes treated by MDI | Experimental | Device: EkiYou V2 |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (12 listed)
- Be over 18 years old;
- Have type 1, type 2, or pancreatogenic diabetes;
- Have been treated with multiple daily injections of insulin in a basal/bolus regimen for at least 6 months;
- Be using a continuous glucose monitoring device such as Dexcom G6, Dexcom One or Freestyle Libre for at least 2 weeks;
- Have a time in the glycemic target range (70-180 mg/dl) of less than 70%;
Key exclusion criteria (11 listed)
- Ketoacidosis or severe level 3 hypoglycemia requiring third-party intervention within 6 months prior to inclusion;
- Treatment with any hypoglycemia-inducing agent other than insulin (including sulfonylureas and SGLT-2 inhibitors);
- Daily insulin requirement exceeding 200 U/day;
- Suffering from gastroparesis;
- Pancreatopathy secondary to chronic alcoholism;
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| EkiYou V2Use of a mobile application that help users to evaluate their daily bolus and basal insulin needs, and that adjusts at weekly basis their insulin to carb ratios, correction factor and basal dose. | Device | Adults with diabetes treated by MDI |
Primary outcome
Change in the percentage of time in range 70-180 mg/dL
Time frame: Through study completion, an average of 8 weeks
Time in range is the amount of time spent in the target glucose range-between 70 and 180 mg/dL-as measured by CGM
39 secondary outcomes
Number of non-serious adverse events related or unrelated to the device
Time frame: Through study completion, an average of 8 weeks
Number of non-serious adverse events related or unrelated to the device
Time frame: Through study completion, an average of 8 weeks
Number of serious clinical adverse events (SAEs)
Time frame: Through study completion, an average of 8 weeks
Number of serious clinical adverse events (SAEs)
Time frame: Through study completion, an average of 8 weeks
Number of other serious adverse events related or unrelated to the device
Time frame: Through study completion, an average of 8 weeks
Number of non-serious and unexpected adverse events related to the device
Time frame: Through study completion, an average of 8 weeks
Change in the percentage of time below 54 mg/dL
Time frame: 2 weeks follow-up
Change in the percentage of time below 54 mg/dL
Time frame: 8 weeks follow-up
Change in the percentage of time below 70 mg/dL
Time frame: 2 weeks follow-up
Change in the percentage of time below 70 mg/dL
Time frame: 8 weeks follow-up
Change in the percentage of time above 180 mg/dL
Time frame: 2 weeks follow-up
Change in the percentage of time above 180 mg/dL
Time frame: 8 weeks follow-up
Change in the percentage of time above 250 mg/dL
Time frame: 2 weeks follow-up
Change in the percentage of time above 250 mg/dL
Time frame: 8 weeks follow-up
Change in the Glucose Management Indicator (GMI)
Time frame: 2 weeks follow-up
Change in the Glucose Management Indicator (GMI)
Time frame: 8 weeks follow-up
Percentage of patients with time in range 70-180 mg/dL above or equal to 70%
Time frame: 2 weeks follow-up
Percentage of patients with time in range 70-180 mg/dL above or equal to 70%
Time frame: 8 weeks follow-up
Change in Mean blood glucose level
Time frame: 2 weeks follow-up
Change in Mean blood glucose level
Time frame: 8 weeks follow-up
Change in Coefficient of variation of blood glucose
Time frame: 2 weeks follow-up
Change in Coefficient of variation of blood glucose
Time frame: 8 weeks follow-up
Number of level 2 hypoglycemic episodes
Time frame: 2 weeks follow-up
Number of level 2 hypoglycemic episodes
Time frame: 8 weeks follow-up
Total Daily Insulin (Units/kg)
Time frame: 2 weeks follow-up
Change in Total Daily Insulin (Units/kg)
Time frame: 8 weeks follow-up
Total Insulin Delivered Via Basal (Units/kg)
Time frame: 2 weeks follow-up
Change in total Insulin Delivered Via Basal (Units/kg)
Time frame: 8 weeks follow-up
Number per day and total Insulin Delivered Via Bolus (Units/kg)
Time frame: 2 weeks follow-up
Change in number per day and total Insulin Delivered Via Bolus (Units/kg)
Time frame: 8 weeks follow-up
Number of connectivity issues with the application reported by the user
Time frame: 8 weeks follow-up
Questionnaire System Usability scale
Time frame: 8 weeks follow-up
Diabetes Treatment Satisfaction Questionnaire (DTSQ)
Time frame: At inclusion visit
Diabetes Treatment Satisfaction Questionnaire (DTSQ)
Time frame: 8 weeks follow-up
Hypoglycemia Fear Survey 2 (HFS II)
Time frame: At inclusion visit
Hypoglycemia Fear Survey 2 (HFS II)
Time frame: 8 weeks follow-up
Number of daily insulin injections calculated from application data
Time frame: 8 weeks follow-up
Average number of daily interactions calculated from application data
Time frame: 8 weeks follow-up
Number of active application users
Time frame: 8 weeks follow-up
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 15 Sep 2025.
Related trials for Diabetes Type 1
Not yet recruitingPhase 3
A Study to Evaluate the Effectiveness and Safety of the Drug AZD6234 for Managing Weight in Adults Who Are Obese or Overweight. These Participants May or May Not Also Have Type 2 Diabetes
Obesity, Overweight
RecruitingPhase 1
Pharmacokinetics, Safety, and Immunogenicity Comparison of Bmab1700 and Opdivo® as Adjuvant Monotherapy in Participants With Melanoma
Melanoma
Active, not recruitingPhase 2
A Study of Botensilimab and Balstilimab for the Treatment of Colorectal Cancer
Metastatic Colorectal Cancer
Not yet recruiting
Inter-Arm Differences in Continuous Glucose Monitor Readings in Adults With Diabetes
Continuous Glucose Monitoring, Type 1 Diabetes
RecruitingObservational study
Estimated Risk of Preeclampsia in the First Trimester and Its Association With Subclinical Atherosclerosis and Cardiovascular Risk in Women With Type 1 Diabetes
Type 1 Diabetes, Preeclampsia
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Orianne VILLARD, MD principal investigator
CHU de Montpellier
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing EkiYou V2 in people with Diabetes Type 1 and Diabetes Type 2 on Insulin, run by University Hospital, Montpellier at 1 site in France.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 12 inclusion and 11 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 15 Sep 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in France. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Change in the percentage of time in range 70-180 mg/dL (time frame: Through study completion, an average of 8 weeks). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 15 Sep 2025.